Skip to content
Vaidya Sane Ayurved Laboratories logo

Vaidya Sane Ayurved Laboratories

MADHAVBAUG NSE
₹155.35 +21.85 (+16.37%)
P/E
18.72
View as Markdown
MCP
Close 4 Nov 2026 ₹155.35 −108.55 −41.1% 1Y
Start ₹263.90

Key Fundamentals

SMEHealthcare Equipment & SuppliesHealthcare

Price-based figures as of · TTM

ROCE
15.10%
Debt to Equity
0.03
EPS (TTM)
₹8.30
Book Value
₹68.17
Market Cap
—
P/E (TTM)
18.72
P/B
2.28
ROE
12.00%
Dividend Yield
0.37%
EBITDA
₹15.42 Cr
52W High
₹335.00
52W Low
₹131.05
Day Range
₹150.00 – ₹155.35
Volume
800

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

51 Average

Data confidence 98/100

Category scores

Quality
48
Average
Returns, margins, earnings quality 22% weight
Valuation
59
Good
Cheap vs sector & own history 24% weight
Growth
64
Good
Sales & profit trajectory 9% weight
Financial Health
84
Strong
Solvency, leverage, coverage 9% weight
Momentum
14
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 10.2% over last 3 years.
  • Working capital days have increased from 41.3 days to 112 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1054
OscillatorsBearish351
Moving AveragesStrong Bearish703

Key readings

RSI (14)
49.71
Neutral
MACD (12,26,9)
−7.34
Bearish
SMA (50)
162.54
Bearish
SMA (200)
202.93
Bearish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
3Y+2.62%
1Y+18.89%

Net profit

Net profit growth by window
3Y+21.64%
1Y+28.57%

Operating cash flow

Operating cash flow growth by window
3YZero base
1Y−54.55%

Operating margin· change in pp

Operating margin growth by window
3Y+4.93 pp
1Y−0.42 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2023₹99.00 Cr
Mar 2024₹99.00 Cr
Mar 2025₹90.00 Cr
Mar 2026₹107 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2023₹5.00 Cr
Mar 2024₹2.00 Cr
Mar 2025₹7.00 Cr
Mar 2026₹9.00 Cr

Half-yearly Results

₹ Cr
MADHAVBAUG half-yearly results, ₹ crore
Particulars Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
46
54
51
48
42
48
50
57
Expenses
41
50
48
46
36
40
41
50
Operating Profit
4
4
3
2
6
9
9
7
OPM %
9%
7%
5%
3.8%
14%
18%
17%
12%
Other Income
1
1
1
1
1
0
1
1
Interest
0
0
0
0
0
1
0
1
Depreciation
1
1
2
2
2
2
3
3
PBT
4
3
2
1
5
5
6
4
Tax %
27%
23%
25%
37%
21%
34%
25%
4%
Net Profit
3
2
1
1
4
3
5
4
EPS (₹)
2.6
1.99
1.12
0.76
3.58
3.21
4.59
3.96

Profit & Loss

₹ Cr
MADHAVBAUG profit and loss, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Sales
99
99
90
107
Expenses
91
95
76
91
Operating Profit
9
5
13
15
OPM %
9%
4.5%
15%
14%
Other Income
1
2
1
2
Interest
1
0
0
1
Depreciation
3
3
4
6
PBT
6
3
10
11
Tax %
25%
30%
28%
17%
Net Profit
5
2
7
9
EPS (₹)
4.59
1.88
6.8
8.55
Div. Payout %
5%
0%
0%
0%

Balance Sheet

₹ Cr
MADHAVBAUG balance sheet, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
11
11
11
11
Reserves
30
45
52
77
Borrowings
0
2
1
3
Other Liabilities
14
12
13
14
Total Liabilities
55
70
77
105
Fixed Assets
21
28
34
35
CWIP
2
2
1
2
Investments
15
18
21
40
Other Assets
17
21
20
28
Total Assets
55
70
77
105

Cash Flow

₹ Cr
MADHAVBAUG cash flow, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
−1
11
5
Investing
1
−13
−10
−24
Financing
−1
15
−1
17
Net Cash Flow
−1
1
0
−2
Free Cash Flow
−7
−12
2
−2
CFO/OP
31
−9
93
49

Ratios

MADHAVBAUG financial ratios, annual
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
22
22
31
35
Inventory Days
—
58
82
70
Days Payable
—
101
149
127
Cash Conversion Cycle
22
−20
−37
−21
Working Capital Days
−2
5
7
112
ROCE %
—
6%
18%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vaidya Sane Ayurved Laboratories insights

57 extracted metrics across FY19–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 66.34%
  • Public 22.85%
  • Others 10.82%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Vaidya Sane Ayurved Laboratories

What does Vaidya Sane Ayurved Laboratories Ltd do?
Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running of hospitals & clinics, and sale of Ayurved based medicines
Where is Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) listed?
Vaidya Sane Ayurved Laboratories Ltd trades as MADHAVBAUG on the NSE.
Which sector does Vaidya Sane Ayurved Laboratories Ltd belong to?
Vaidya Sane Ayurved Laboratories Ltd is classified under the Healthcare sector, in the Medical Equipment industry.
What is the PE ratio of Vaidya Sane Ayurved Laboratories Ltd?
Vaidya Sane Ayurved Laboratories Ltd trades at a PE ratio of 18.72 as of 4 Nov 2026, on earnings per share of ₹8.3, against a book value of ₹68.17 per share.
What is the 52-week high and low of Vaidya Sane Ayurved Laboratories Ltd?
Over the last 52 weeks Vaidya Sane Ayurved Laboratories Ltd has traded between ₹131.05 and ₹335 as of 4 Nov 2026.
Does Vaidya Sane Ayurved Laboratories Ltd pay dividends?
Vaidya Sane Ayurved Laboratories Ltd has a dividend yield of 0.37%.
What is the Return on Equity (ROE) of Vaidya Sane Ayurved Laboratories Ltd?
Vaidya Sane Ayurved Laboratories Ltd reported a return on equity of 12.00%. Its debt-to-equity ratio is 0.03.

Company Information

Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running of hospitals & clinics, and sale of Ayurved based medicines

Website madhavbaug.org
Listed 23 Feb 2022
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MADHAVBAUG.md for Vaidya Sane Ayurved Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Healthcare Equipment stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month